AI assistant
Niagen Bioscience, Inc. — Director's Dealing 2008
Jun 26, 2008
32418_dirs_2008-06-25_ca6e0849-a766-49f2-ae31-333315c1a608.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: ChromaDex Corp. (CDYE(4))
CIK: 0001386570
Period of Report: 2008-06-25
Reporting Person: GERMAIN MARK (Director)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 2053995 | Indirect |
| Common Stock | 696335 | Indirect |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Options (right to buy) | $1.5 | 2017-12-21 | Common Stock (30000) | Direct | |
| Stock Options (right to buy) | $1.5 | 2018-04-21 | Common Stock (250000) | Direct |
Footnotes
F1: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F2: 6,000 stock options become exercisable annually beginning December 21, 2008.
F3: 62,500 options become exercisable on April 21, 2009 and 3,906 options become exercisable monthly thereafter except that 3,907 options become exercisable every fourth month.